B. Feinberg (Dublin, OH, United States of America)
Cardinal Health Specialty SolutionsAuthor Of 1 Presentation
116P - Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2- metastatic breast cancer patients in the United States
Abstract
Background
Eribulin mesylate was approved in the US in 2010 for metastatic breast cancer (mBC) following at least two chemotherapeutic regimens; prior therapy should include anthracycline and taxane in the adjuvant or metastatic setting. With the changing treatment landscape in HR+/HER2- mBC, the main objective of our analyses was to assess the real-world clinical effectiveness of eribulin in HR+/HER2- mBC, when prescribed consistent with the US label.
Methods
A retrospective chart review study of mBC patients initiating eribulin per US label between 2011-2017 was conducted across US community oncology practices. De-identified data were extracted by prescribing physicians from patients’ medical records and captured via an electronic case report form. Clinical outcomes assessed included provider-reported best overall response (defined as complete + partial response), progression-free survival (PFS), and overall survival (OS) in the HR+/HER2- mBC patients overall and those treated with eribulin post cyclin-dependent kinase inhibitor (CDKi), respectively.
Results
A total of 233 mBC patients with HR+/HER2- subtype treated with eribulin met the study inclusion criteria: mean age was 61 years and 55% had an ECOG status of 0 or 1. Median duration of eribulin treatment was 5.8 months, with 67% treated in 3rd line and 33% in ≥4th line. Best overall response on eribulin was 52% and median PFS for eribulin was estimated at 6.1 months. Landmark OS at 12 and 24 months was 46% and 26%, respectively. Approximately 31% (n=72) of the HR+/HER2- mBC patients had received a CDKi prior to eribulin. In the post CDKi subgroup, median duration of eribulin treatment was 4.5 months, and 74% were treated in 4th line or later. Best overall response on eribulin was 40%. Median PFS for eribulin in the post CDKi subgroup was estimated to be 4.6 months. Landmark OS at 12 and 24 months in the post CDKi subgroup was 39% and 19%, respectively.
Conclusions
Results of these retrospective analyses reinforce the clinical effectiveness of eribulin in HR+/HER2- mBC patients including those previously treated with a CDKi, when used in accordance with the eribulin US label in clinical practice.
Legal entity responsible for the study
Eisai Inc.
Funding
Eisai Inc.
Disclosure
S.S. Mougalian: Honoraria (self): Eisai Inc.; Honoraria (self): Celgene Corporation; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Genentech. J. Zhang: Full/Part-time employment, Eisai Inc. is the study sponsor: Eisai Inc. J.K. Kish, M.E. Zettler, B.A. Feinberg: Full/Part-time employment, Cardinal Health is a consultant to Eisai Inc. of this research: Cardinal Health Specialty Solutions.